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Abstract
The Researching Severe Sepsis and Organ Dysfunction in
Children: A Global Perspective study of drotrecogin alfa activated
versus placebo was the largest study of adjunctive therapy ever
performed in children with severe sepsis. Despite this, the study
failed to show any significant differences in outcome between the
treatment and placebo groups. The results raise questions about
how we should perform meaningful clinical trials in relatively rare
conditions such as paediatric sepsis, where the easily measurable
endpoints (such as death) are infrequent. A radical rethink of the
design of such studies is urgently needed.
The efficacy and safety of drotrecogin alfa activated (DrotAA)
(recombinant human activated protein C) was assessed in
children with severe sepsis in the Researching Severe Sepsis
and Organ Dysfunction in Children: A Global Perspective
(RESOLVE) study [1]. In this double-blind, randomised,
placebo-controlled, multicentre, multinational trial, 477 patients
were enrolled at 104 study sites.
Children with severe sepsis were randomly assigned to a 4-
day course of DrotAA or placebo. The primary endpoint was
a novel score: the composite time to complete organ failure
resolution. Secondary endpoints were the all-cause mortality
up to 28 days after treatment, and safety. The primary end-
point was derived in an attempt to determine clinically useful
endpoints of morbidity, which both clinicians and patients
and their families would view as a tangible outcome
(including cessation of vasopressor therapy, extubation and
cessation of renal replacement therapy). This novel score,
however, like many other scores introduced for the purposes
of trial design, has been criticised for generating abstract
numbers lacking clear clinical applicability, and for being
substantially affected by early mortality events and differ-
ences in local management protocols for organ dysfunction
(for example, ventilator-weaning protocols, use of blood
products and removal of renal replacement therapy) resulting
from such a widespread participation of recruiting centres [2].
The RESOLVE study failed to find any clear benefit for the
use of DrotAA in children with severe sepsis in the study
population as a whole, or in any specific subgroup, either
previously defined or after post-hoc analysis. The RESOLVE
study did, however, produce some important findings. It was
the largest study ever performed in children with severe
sepsis, and thus helped to define both the natural history of
sepsis in children and the incidence of important
complications such as sepsis-induced organ failure and
bleeding events.
In the RESOLVE study, patients with the most severe
coagulation abnormalities appeared to benefit most from
DrotAA, suggesting this group of patients may be a valuable
population for further study. In addition, intracranial bleeding
events were more common with DrotAA than with placebo
(five events during infusion, four of which occurred in infants
<2 months, versus one event during infusion, respectively),
even though overall bleeding events were similar between the
treatment and placebo groups. In view of these results, and of
the known increased likelihood of bleeding in early infancy,
future trials of DrotAA, and probably other anticoagulants,
should avoid enrolling patients of this age.
The disappointing results of the RESOLVE study raise
important questions about the overall efficacy of DrotAA. In
particular, the negative results of the RESOLVE trial bring
into question the results of the Recombinant Human Protein
C Worldwide Evaluation in Severe Sepsis (PROWESS) study,
the first phase III study of DrotAA in adults with severe sepsis
or septic shock. The PROWESS trial was the first study of any
adjunctive therapy for sepsis to have produced a statistically
significant benefit in the study population overall [3].
Knowledge of the mechanisms of action of activated protein
C suggests that is likely to extend beyond its well-
documented antithrombotic effects. Activated protein C has
been shown to have endothelial cell protective effects and to
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limit interactions between endothelial cells and neutrophils in
sepsis, as well as inhibiting production of inflammatory
mediators by monocytes and macrophages. This suggests
that activated protein C is likely to have potential as an anti-
inflammatory compound as well as an anticoagulant and
profibrinolytic, and thus has potential to interrupt the
pathophysiological processes occurring in severe sepsis,
making it probably beneficial in such patients [4].
Children with severe sepsis remain at significant risk of death
without any hope of effective adjunctive therapies on the
horizon. The relative rarity of severe paediatric sepsis coupled
with its relatively low mortality make meaningful clinical
studies difficult or impossible to perform. In addition,
pharmaceutical companies are reluctant to address severe
sepsis in children due to the difficulties in designing
appropriate studies and the huge costs involved with limited
prospects of financial return, despite rulings from regulatory
authorities stating that all licensed agents should be fully
evaluated in children [5].
What is needed is a rethink of paediatric sepsis studies.
There are 2,000 children admitted to paediatric intensive care
units in the United Kingdom each year with presumed sepsis,
with approximately 20% mortality [6]. Intensivists are failing
these children due to the lack of well-defined clinical studies.
The paediatric intensive care community is developing a
coordinated network for collaborative clinical studies [7], but
we need to do more. Routine therapies should be
standardised according to protocol, thus removing hetero-
geneity of therapies between centres. Ethical obstacles could
be overcome by removing the need for parental consent to
administer adjunctive therapies (once safety concerns have
been addressed through appropriate clinical studies), with
the assumption of therapeutic equivalence – therefore
enabling all children with severe sepsis admitted to
designated paediatric intensive care units to be enrolled in
clinical trials. Standardised therapeutic regimens and study
agents can thus be assessed in a logical and sequential
pattern determined by the diagnosis of severe sepsis, in a
rational scientific manner, much as new therapies for
childhood leukaemia have been evaluated.
Children are also less likely than adults to have significant
underlying co-morbidity and are a more homogeneous popu-
lation than are recruited to adult sepsis studies. Children
may therefore be a much more suitable population to
evaluate newer therapies in a controlled trial setting, to
establish proof of principal and then allow extension of
studies into adult trial populations, rather than studies in
adults preceding studies in children.
Only by a radical rethink of the way we evaluate new
therapies in critically ill children will we be able to properly
assess experimental treatment modalities, thus allowing
children with sepsis at high risk of death to benefit maximally
from adjunctive therapies.
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